|

NIO752 Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 2

Top Sponsors

  • University College, London1
  • Novartis Pharmaceuticals1

Indications

  • Alzheimer's Disease2
  • Alzheimer Disease2
  • Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)1
  • Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder)1
  • Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)1

Other1 trial

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1

St Louis, Missouri1 trial

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

Washington University in St. Louis

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.